Danaher Corporation (DHR): Executive Vice President sold ~$3.68M

~$3.68M

Approx. value · 16K sh @ $236.09

13K

Holds after · shares reported

Traded

Oct 28, 2026

Filed

Oct 29, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 31, 2026CongressDisclosed sale of DHR — reported range $15,001 - $50,000
2. Sep 2, 2026FDARecall: DxC 500 AU Clinical Chemistry Analyzers: 1. AU w/out ISE, Part No. C63519 2. AU w/ISE, Part No. C63520
3. Sep 2, 2026FDARecall: DxC 500i Clinical Analyzer Modules: 1. DxC 500 AU Module w/ISE, DxC 500i, Part No. C63522 2. DxC 500 AU Module, DxC 500i, Part No. C63521 3. Access 2 Module, D…
4. Sep 2, 2026CongressDisclosed partial sale of DHR — reported range $1,001 - $15,000
5. Sep 21, 2026FDAFDA device clearance: Access NT-proBNP
6. Sep 21, 2026FDARecall: ROTOR ASSY-SW41, Reference Number 331362, when the rotors are installed in the following centrifuges: Optima XPN-100 (Model Numbers A99846 and A94469), Optima…
7. Sep 21, 2026FDARecall: ROTOR ASSY-SW40, Reference Number 331302, when the rotors are installed in the following centrifuges: Optima XPN-100 (Model Numbers A99846 and A94469), Optima…
8. Sep 25, 2026FDAFDA device clearance: Xpert Respiratory Panel
9. Oct 9, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 9, 2026, the Board of Directors (the “Board”) of Danaher Corporation (the “Company” or “Danaher”) increased the size of the Board to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg to the Board, in each case effective immediately.”
10. Oct 19, 2026FDAFDA device clearance: Access MeMed BV
11. Oct 20, 2026FDAFDA device clearance: Access BNP II
12. Oct 21, 2026Company filing · Form 8-K · ResultsReported its results
13. Oct 28, 2026 · this disclosureInsiderOfficer sold ~$3.68M of DHR shares in the open market

What came next

1. Oct 28, 2026Insider · 2 peopleInsiders: 3 sales (~$5.1M)
2. Oct 30, 2026FDAFDA device clearance: Xpert® Hemorrhagic Fever Panel
3. Nov 5, 20265% stakeFMR LLC reported a passive stake (13G) of 5.6%
4. Nov 9, 2026Insider · 2 peopleInsiders: 2 sales (~$4.6M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Danaher Corporation

For Danaher Corporation, OQRO holds 14 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DHR page.

Other recent filings by Matthew Mcgrew, Executive Vice President

• SEC Form 4 at Danaher Corporation (DHR)Nov 10, 2026
• SEC Form 4 at Danaher Corporation (DHR)Oct 29, 2026
• SEC Form 4 at Danaher Corporation (DHR)Nov 13, 2025

The full history of Matthew Mcgrew, Executive Vice President is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Danaher Corporation

• SEC Form 144Nov 10, 2026
• SEC Form 4Nov 10, 2026
• SEC Form 4Nov 10, 2026
• SEC Form 144Nov 9, 2026
• SEC Form 144Nov 9, 2026
• SEC Form 144Nov 9, 2026

Everything OQRO holds on this company is on its DHR page.